It's been a pretty great week for Prestige Consumer Healthcare Inc. (NYSE:PBH) shareholders, with its shares surging 13% to US$87.00 in the week since its latest third-quarter results. The result was positive overall - although revenues of US$290m were in line with what the analysts predicted, Prestige Consumer Healthcare surprised by delivering a statutory profit of US$1.22 per share, modestly greater than expected. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Check out our latest analysis for Prestige Consumer Healthcare

Taking into account the latest results, the consensus forecast from Prestige Consumer Healthcare's eight analysts is for revenues of US$1.18b in 2026. This reflects a credible 5.6% improvement in revenue compared to the last 12 months. Per-share earnings are expected to swell 17% to US$5.03. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$1.16b and earnings per share (EPS) of US$4.76 in 2026. So the consensus seems to have become somewhat more optimistic on Prestige Consumer Healthcare's earnings potential following these results.

The consensus price target was unchanged at US$88.29, implying that the improved earnings outlook is not expected to have a long term impact on value creation for shareholders. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. Currently, the most bullish analyst values Prestige Consumer Healthcare at US$104 per share, while the most bearish prices it at US$75.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. We can infer from the latest estimates that forecasts expect a continuation of Prestige Consumer Healthcare'shistorical trends, as the 4.4% annualised revenue growth to the end of 2026 is roughly in line with the 4.1% annual growth over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenues grow 8.7% per year. So although Prestige Consumer Healthcare is expected to maintain its revenue growth rate, it's forecast to grow slower than the wider industry.

The Bottom Line

The most important thing here is that the analysts upgraded their earnings per share estimates, suggesting that there has been a clear increase in optimism towards Prestige Consumer Healthcare following these results. On the plus side, there were no major changes to revenue estimates; although forecasts imply they will perform worse than the wider industry. The consensus price target held steady at US$88.29, with the latest estimates not enough to have an impact on their price targets.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Prestige Consumer Healthcare going out to 2027, and you can see them free on our platform here..

You still need to take note of risks, for example - Prestige Consumer Healthcare has 2 warning signs we think you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.